Phase I CARLYSLE trial data show CAR-T therapy obe-cel induces remission in severe refractory lupus with a favorable safety profile. Separate case report documents two successful pregnancies after dual-target CAR-T therapy with no transmission to infants.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07400029 |
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia |
RECRUITING | PHASE2 |
| NCT07053800 |
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) |
RECRUITING | PHASE2 |
